Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Role of ctDNA in Breast Cancer

  • Sant, Marta
  • Bernat-Peguera, Adrià|||0000-0002-3108-0571
  • Felip, Eudald|||0000-0002-3812-1313
  • Margelí, Mireia|||0000-0003-3594-4530
Circulating tumor DNA is DNA released by the tumor into the bloodstream. In breast cancer, it is used mainly in research or in clinical trials, but it will likely be used in routine clinical practice once certain issues have been worked out and methods of analysis have been improved and standardized. Breast cancer classification and treatment selection are now based on analysis of the tumor but circulating tumor DNA carries many features of the original tumor and can be analyzed from a simple, non-invasive blood extraction. Here, we review its potential role in early breast cancer (for screening, diagnosis, detection of minimal residual disease after surgery, follow up, and treatment) and in metastatic breast cancer (for the detection of mutations, prognosis and treatment). Breast cancer is currently classified by immunohistochemistry. However, technological advances in the detection of circulating tumor DNA (ctDNA) have made new options available for diagnosis, classification, biological knowledge, and treatment selection. Breast cancer is a heterogeneous disease and ctDNA can accurately reflect this heterogeneity, allowing us to detect, monitor, and understand the evolution of the disease. Breast cancer patients have higher levels of circulating DNA than healthy subjects, and ctDNA can be used for different objectives at different timepoints of the disease, ranging from screening and early detection to monitoring for resistance mutations in advanced disease. In early breast cancer, ctDNA clearance has been associated with higher rates of complete pathological response after neoadjuvant treatment and with fewer recurrences after radical treatments. In metastatic disease, ctDNA can help select the optimal sequencing of treatments. In the future, thanks to new bioinformatics tools, the use of ctDNA in breast cancer will become more frequent, enhancing our knowledge of the biology of tumors. Moreover, deep learning algorithms may also be able to predict breast cancer evolution or treatment sensitivity. In the coming years, continued research and the improvement of liquid biopsy techniques will be key to the implementation of ctDNA analysis in routine clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types

  • Felip, Eudald|||0000-0002-3812-1313
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Gómez, Maica
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Romeo, Margarita|||0000-0003-1725-8115
  • Morán, Teresa
  • Layos, Laura
  • Pérez-Roca, Laia|||0000-0002-8400-1339
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Fernández, Pedro Luis|||0000-0002-8618-4597
  • Mesia, Ricard|||0000-0002-3785-3563
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Ballana, Ester|||0000-0002-5215-7363
  • Margelí, Mireia|||0000-0003-3594-4530
Ample evidence exists connecting dNTP pool dysregulation to cancer and genomic instability. SAMHD1, the unique dNTP triphosphohydrolase described in humans, has been proposed to play a key role in hematological cancers, although its value in advanced solid tumors has not yet been explored. Moreover, it has been proposed that SAMHD1 might fulfill the requirements of a driver gene in tumor development or might promote a so-called mutator phenotype. Here, we show that low SAMHD1 expression tumors show better prognosis in breast, ovarian, and lung advanced cancer. Moreover, low SAMHD1 expression is a positive predictive factor in lung and ovarian cancer treated with platin derivates and/or antimetabolites. In vitro evaluation of its underlying mechanism revealed that SAMHD1 KO cells presented enhanced susceptibility to DNA damage and subsequent induction of apoptosis of tumor cells. Our results provide strong evidence of the clinical importance of SAMHD1, becoming an interesting target for the development of personalized cancer treatments. SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase with important roles in the control of cell proliferation and apoptosis, either through the regulation of intracellular dNTPs levels or the modulation of the DNA damage response. However, SAMHD1's role in cancer evolution is still unknown. We performed the first in-depth study of SAMHD1's role in advanced solid tumors, by analyzing samples of 128 patients treated with chemotherapy agents based on platinum derivatives and/or antimetabolites, developing novel in vitro knock-out models to explore the mechanisms driving SAMHD1 function in cancer. Low (or no) expression of SAMHD1 was associated with a positive prognosis in breast, ovarian, and non-small cell lung cancer (NSCLC) cancer patients. A predictive value was associated with low-SAMHD1 expression in NSCLC and ovarian patients treated with antimetabolites in combination with platinum derivatives. In vitro, SAMHD1 knock-out cells showed increased γ-H2AX and apoptosis, suggesting that SAMHD1 depletion induces DNA damage leading to cell death. In vitro treatment with platinum-derived drugs significantly enhanced γ-H2AX and apoptotic markers expression in knock-out cells, indicating a synergic effect of SAMHD1 depletion and platinum-based treatment. SAMHD1 expression represents a new strong prognostic and predictive biomarker in solid tumors and, thus, modulation of the SAMHD1 function may constitute a promising target for the improvement of cancer therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer

  • Ferrando Díez, Angelica|||0000-0003-0206-7498
  • Felip, Eudald|||0000-0002-3812-1313
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Pous, Anna
  • Sirven, Milana Bergamino
  • Margelí, Mireia|||0000-0003-3594-4530
Despite the improvement achieved by the introduction of HER2-targeted therapy, up to 25% of early human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients will relapse. Beyond trastuzumab, other agents approved for early HER2+ BC include the monoclonal antibody pertuzumab, the antibody-drug conjugate (ADC) trastuzumab-emtansine (T- DM1) and the reversible HER2 inhibitor lapatinib. New agents, such as trastuzumab-deruxtecan or tucatinib in combination with capecitabine and trastuzumab, have also shown a significant improvement in the metastatic setting. Other therapeutic strategies to overcome treatment resistance have been explored in HER2+ BC, mainly in HER2+ that also overexpress estrogen receptors (ER+). In ER+ HER2+ patients, target therapies such as phosphoinositide-3-kinase (PI3K) pathway inhibition or cyclin-dependent kinases 4/6 blocking may be effective in controlling downstream of HER2 and many of the cellular pathways associated with resistance to HER2-targeted therapies. Multiple trials have explored these strategies with some promising results, and probably, in the next years conclusive results will succeed. In addition, HER2+ BC is known to be more immunogenic than other BC subgroups, with high variability between tumors. Different immunotherapeutic agents such as HER-2 therapy plus checkpoint inhibitors, or new vaccines approaches have been investi-gated in this setting, with promising but controversial results obtained to date.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection

  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Felip, Eudald|||0000-0002-3812-1313
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Calba, Ignasi
  • Massanella, Marta|||0000-0002-3326-151X
  • Sirera, Guillem|||0000-0003-4014-9355
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • Badia, Roger|||0000-0003-3982-7577
HIV latent infection may be associated with disrupted viral RNA sensing, interferon (IFN) signaling, and/or IFN stimulating genes (ISG) activation. Here, we evaluated the use of compounds selectively targeting at the inhibitor of nuclear factor-κB (IκB) kinase (IKK) complex subunits and related kinases (TBK1) as a novel pathway to reverse HIV-1 latency in latently infected non-clonal lymphoid and myeloid cell in vitro models. IKK inhibitors (IKKis) triggered up to a 1.8-fold increase in HIV reactivation in both, myeloid and lymphoid cell models. The best-in-class IKKis, targeting TBK-1 (MRT67307) and IKKβ (TCPA-1) respectively, were also able to significantly induce viral reactivation in CD4+ T cells from people living with HIV (PLWH) ex vivo. More importantly, although none of the compounds tested showed antiviral activity, the combination of the distinct IKKis with ART did not affect the latency reactivation nor blockade of HIV infection by ART. Finally, as expected, IKKis did not upregulate cell activation markers in primary lymphocytes and innate immune signaling was blocked, resulting in downregulation of inflammatory cytokines. Overall, our results support a dual role of IKKis as immune modulators being able to tackle the HIV latent reservoir in lymphoid and myeloid cellular models and putatively control the hyperinflammatory responses in chronic HIV-1 infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Felip, Eudald|||0000-0002-3812-1313
  • Castellà Fernández, Eva
  • Quiroga García, Vanesa
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Angelats, Laura
  • Esteve, Anna|||0000-0002-1962-971X
  • Pérez-Roca, Laia|||0000-0002-8400-1339
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Fernandez, Pedro Luis
  • Ferrando Díez, Angelica|||0000-0003-0206-7498
  • Pous, Anna
  • Bergamino, Milana|||0000-0002-1091-2711
  • Cirauqui, Beatriz|||0000-0002-0136-8056
  • Romeo, Marga
  • Teruel, Iris|||0000-0002-5563-6562
  • Mesia, Ricard|||0000-0002-3785-3563
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
The lack of validated surrogate biomarkers is still an unmet clinical need in the management of early breast cancer cases that do not achieve complete pathological response after neoadjuvant chemotherapy (NACT). Here, we describe and validate the use of SAMHD1 expression as a prognostic biomarker in residual disease in vivo and in vitro. SAMHD1 expression was evaluated in a clinical cohort of early breast cancer patients with stage II-III treated with NACT. Heterotypic 3D cultures including tumor and immune cells were used to investigate the molecular mechanisms responsible of SAMHD1 depletion through whole transcriptomic profiling, immune infiltration capacity and subsequent delineation of dysregulated immune signaling pathways. SAMHD1 expression was associated to increased risk of recurrence and higher Ki67 levels in post-NACT tumor biopsies of breast cancer patients with residual disease. Survival analysis showed that SAMHD1-expressing tumors presented shorter time-to-progression and overall survival than SAMHD1 negative cases, suggesting that SAMHD1 expression is a relevant prognostic factor in breast cancer. Whole-transcriptomic profiling of SAMHD1-depleted tumors identified downregulation of IL-12 signaling pathway as the molecular mechanism determining breast cancer prognosis. The reduced interleukin signaling upon SAMHD1 depletion induced changes in immune cell infiltration capacity in 3D heterotypic in vitro culture models, confirming the role of the SAMHD1 as a regulator of breast cancer prognosis through the induction of changes in immune response and tumor microenvironment. SAMHD1 expression is a novel prognostic biomarker in early breast cancer that impacts immune-mediated signaling and differentially regulates inflammatory intra-tumoral response. The online version contains supplementary material available at 10.1007/s13402-023-00862-1.